|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Janux Therapeutics, Inc. (JANX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
39,900,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Janux Therapeutics is a biopharmaceutical company engaged in the development of a pipeline of immunotherapies by applying Co.'s proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and TRACIr platforms to treat patients suffering from cancer. Co.'s initial focus is on developing a class of T cell engagers, and Co.'s primary product candidates are designed to target clinically validated drug targets. Co. is developing a pipeline with programs targeting prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2, with all of Co.'s programs in the preclinical or discovery stage.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
2,549,562 |
3,044,570 |
3,044,570 |
| Total Buy Value |
$0 |
$14,965,929 |
$21,133,729 |
$21,133,729 |
| Total People Bought |
0 |
3 |
4 |
4 |
| Total Buy Transactions |
0 |
3 |
4 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Capps Vickie L |
|
– • – |
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,493 |
65,543 |
|
- |
|
| Gujrathi Sheila |
|
– • – |
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,986 |
108,028 |
|
- |
|
| Avalon Bioventures I, Lp |
10% Owner |
– – • |
2024-02-29 |
4 |
D |
$0.00 |
$0 |
I/I |
(577,478) |
0 |
|
- |
|
| Avalon Bioventures I, Lp |
10% Owner |
– – • |
2024-02-29 |
4 |
A |
$0.00 |
$0 |
I/I |
44,544 |
1,700 |
|
- |
|
| Avalon Bioventures I, Lp |
10% Owner |
– – • |
2024-02-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(438,722) |
3,948,495 |
|
- |
|
| Diraimondo Thomas |
Chief Scientific OfficerOffice |
• – – |
2024-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
101,532 |
|
- |
|
| Reardon Tighe |
Acting Chief Financial Officer |
• – • |
2023-11-13 |
4 |
B |
$5.87 |
$4,988,643 |
I/I |
849,854 |
849,854 |
3.36 |
- |
|
| Lichter Jay |
Director |
– • • |
2023-11-13 |
4 |
B |
$5.87 |
$4,988,643 |
I/I |
849,854 |
849,854 |
2.25 |
- |
|
| Avalon Bioventures I, Lp |
10% Owner |
– – • |
2023-11-13 |
4 |
B |
$5.87 |
$4,988,643 |
I/I |
849,854 |
849,854 |
1.5 |
- |
|
| Shah Rajeev M. |
Director |
– • • |
2023-07-19 |
4 |
B |
$12.46 |
$6,167,800 |
I/I |
495,008 |
8,117,246 |
2.25 |
- |
|
| Thompson Peter A |
Director |
– • – |
2021-12-29 |
4 |
S |
$20.30 |
$820,120 |
I/I |
(40,400) |
231,098 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2021-12-29 |
4 |
S |
$20.30 |
$820,120 |
I/I |
(40,400) |
231,098 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2021-12-21 |
4 |
S |
$19.00 |
$2,268,600 |
I/I |
(119,400) |
234,798 |
|
- |
|
| Thompson Peter A |
Director |
– • – |
2021-12-21 |
4 |
S |
$19.00 |
$2,268,600 |
I/I |
(119,400) |
234,798 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2021-12-16 |
4 |
S |
$19.07 |
$7,500,231 |
I/I |
(393,300) |
245,898 |
|
- |
|
| Thompson Peter A |
Director |
– • – |
2021-12-16 |
4 |
S |
$19.07 |
$7,500,231 |
I/I |
(393,300) |
245,898 |
|
- |
|
| Meyer Andrew Hollman |
Chief Business OfficerOfficer |
• – – |
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
59,416 |
|
- |
|
| Reardon Tighe |
Acting Chief Financial Officer |
• – • |
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
172,935 |
|
- |
|
| Lichter Jay |
Director |
– • • |
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
192,150 |
|
- |
|
| Campbell David Alan |
Chief Executive OfficerOfficer |
• • – |
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
332,054 |
|
- |
|
| Gujrathi Sheila |
Director |
– • – |
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
105,042 |
|
- |
|
| Capps Vickie L |
Director |
– • – |
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
64,050 |
|
- |
|
| Heller Stefan |
Director |
– • – |
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
96,075 |
|
- |
|
| Avalon Bioventures Spv I, L.p. |
10% Owner |
– – • |
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
192,150 |
|
- |
|
24 Records found
|
1
|
Page 1 of 1 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
